RHYTHM PHARMACEUTICALS INC (RYTM)
Health Care · Rare neuroendocrine disease therapeutics · NASDAQ
Rare disease biotech commercializing the first-ever MC4R agonist therapy for genetic obesity and expanding into acquired hypothalamic obesity.
What RHYTHM PHARMACEUTICALS INC does
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company developing melanocortin-4 receptor (MC4R) agonists for rare neuroendocrine diseases characterized by hyperphagia and severe obesity. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved and marketed in the United States, EU, UK, Canada, and other regions for MC4R pathway disorders including Bardet-Biedl syndrome and genetic obesity caused by POMC, PCSK1, or LEPR deficiency. The company is also developing earlier-stage MC4R agonists, bivamelagon and RM-718, and pursuing regulatory approval for IMCIVREE in acquired and congenital hypothalamic obesity.
Themes: ["rare genetic obesity","MC4R pathway diseases","hypothalamic obesity","Bardet-Biedl syndrome","precision medicine / genetic testing","neuroendocrine disorders"]
Fundamentals
- Price$115.48 as of 2026-07-09 close
- Market cap$7.9B as of 2026-07-10
- 1-year return+29.8% as of 2026-07-09 close
- Net margin-93.3% as of 2026-07-10
- Gross margin+89.4% as of 2026-07-10
- ROE-86.5% as of 2026-07-10
- Debt / equity0.46 as of 2026-07-10
- Revenue growth (YoY)+58.7% as of 2026-07-10
- Revenue CAGR (3y)+100.2% SEC XBRL
- Beta1.97 as of 2026-07-10
Key risks (from latest filing)
["Limited patient population for rare MC4R pathway diseases constrains addressable market","Regulatory approval uncertainties for setmelanotide in acquired hypothalamic obesity and for investigational compounds bivamelagon and RM-718","Commercial execution and patient enrollment challenges in rare disease indication; company is unprofitable with significant operating losses"]
Competitors & peers
- Viking Therapeutics (VKING) — GLP-1 agonist obesity
- Amgen (AMGN) — MariTide obesity therapy
- Novo Nordisk (NVO) — GLP-1/GIP agonists
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.